Actinium Pharmaceuticals(ATNM)
$1.35-0.14 (-9.40%)
ATNM
Actinium Pharmaceuticals financials statements
$1.35
At close:-0.14 (-9.40%)
Want to see ATNM full AI Analyst Report?
Actinium Pharmaceuticals (ATNM) Ratios
2,294 Followers
Actinium Pharmaceuticals Ratios
ATNM's free cash flow for Q2 2026 was $-5.66M. For the 2026 fiscal year, ATNM's free cash flow was decreased by $-478.00K and operating cash flow was $-5.18M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.20 | 9.14 | 9.21 | 10.44 | 11.66 |
| Quick Ratio | 6.20 | 9.14 | 9.21 | 10.44 | 11.66 |
| Cash Ratio | 6.02 | 8.95 | 9.03 | 10.25 | 11.38 |
| Solvency Ratio | -0.75 | -0.85 | -1.07 | -0.68 | -3.54 |
| Operating Cash Flow Ratio | -3.08 | -4.06 | -5.57 | 0.81 | -3.05 |
| Short-Term Operating Cash Flow Coverage | -34.04 | 0.00 | -87.50 | 0.00 | 0.00 |
| Net Current Asset Value | $ 5.44M | $ 30.36M | $ 33.20M | $ 63.23M | $ 72.91M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.02 | 0.03 | 0.02 | 0.00 |
| Debt-to-Equity Ratio | 0.22 | 0.05 | 0.06 | 0.04 | 0.00 |
| Debt-to-Capital Ratio | 0.18 | 0.05 | 0.05 | 0.04 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 6.61 | 2.35 | 2.24 | 1.72 | 1.09 |
| Debt Service Coverage Ratio | -45.80 | 0.00 | -94.51 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.05 | 0.05 | 0.08 | 0.11 | 0.02 |
| Net Debt to EBITDA | 1.40 | 1.91 | 1.46 | 3.18 | 3.20 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 0.00% | 100.00% | 100.00% | 54.20% |
| EBIT Margin | -37652.22% | 0.00% | -64098.77% | -3311.07% | -2165.56% |
| EBITDA Margin | -36740.00% | 0.00% | -63123.46% | -3243.20% | -2119.76% |
| Operating Profit Margin | -40274.44% | 0.00% | -64098.77% | -3311.07% | -2182.17% |
| Pretax Profit Margin | -37652.22% | 0.00% | -60269.14% | -3205.53% | -2165.56% |
| Net Profit Margin | -37652.22% | 0.00% | -60269.14% | -3205.53% | -2165.56% |
| Continuous Operations Profit Margin | -37652.22% | 0.00% | -60269.14% | -3205.53% | -2165.56% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 93.49% | 90.79% | 94.03% | 96.81% | 99.24% |
| Return on Assets (ROA) | -65.45% | -49.73% | -59.94% | -28.91% | -30.82% |
| Return on Equity (ROE) | -432.56% | -116.74% | -134.19% | -49.66% | -33.69% |
| Return on Capital Employed (ROCE) | -82.74% | -61.27% | -71.17% | -32.93% | -33.94% |
| Return on Invested Capital (ROIC) | -81.40% | -60.75% | -70.65% | -32.77% | -33.80% |
| Return on Tangible Assets | -65.45% | -49.73% | -59.94% | -28.91% | -30.82% |
| Earnings Yield | -79.87% | -100.94% | -36.12% | -12.84% | -20.04% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.11 | 0.00 | 0.00 | 0.09 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.04 | 0.00 | 0.03 | 0.35 | 1.79 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 |
| Cash Conversion Cycle | 0.00 | -3406.07 | 0.00 | 0.00 | -3855.49 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 3406.07 | 0.00 | 0.00 | 3855.49 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.79 | -1.10 | -1.78 | 0.36 | -1.01 |
| Free Cash Flow Per Share | -0.79 | -1.10 | -1.78 | 0.34 | -1.02 |
| Dividend Paid and CapEx Coverage Ratio | -236.35 | -3006.55 | -309.38 | 23.62 | -156.89 |
| Capital Expenditure Coverage Ratio | -236.35 | -3006.55 | -309.38 | 23.62 | -156.89 |
| Operating Cash Flow Coverage Ratio | -14.51 | -21.02 | -22.40 | 3.35 | -67.31 |
| Operating Cash Flow to Sales Ratio | -273.11 | 0.00 | -584.38 | 8.39 | -18.24 |
| Free Cash Flow Yield | -58.18% | -87.32% | -35.14% | 3.22% | -16.99% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.25 | -0.99 | -2.77 | -7.79 | -4.99 |
| Price-to-Sales (P/S) Ratio | 471.40 | 0.00 | 1668.50 | 249.62 | 108.05 |
| Price-to-Book (P/B) Ratio | 5.42 | 1.16 | 3.72 | 3.87 | 1.68 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.72 | -1.15 | -2.85 | 31.06 | -5.89 |
| Price-to-Operating Cash Flow Ratio | -1.73 | -1.15 | -2.86 | 29.74 | -5.92 |
| Price-to-Earnings Growth (PEG) Ratio | 0.09 | 0.03 | -0.08 | -0.55 | 0.14 |
| Enterprise Value Multiple | 0.12 | 0.89 | -1.18 | -4.51 | -1.90 |
| Enterprise Value | -3.88M | -33.44M | 60.58M | 150.78M | 46.09M |
| EV to EBITDA | 0.12 | 0.89 | -1.18 | -4.51 | -1.90 |
| EV to Sales | -43.08 | 0.00 | 747.95 | 146.39 | 40.29 |
| EV to Free Cash Flow | 0.16 | 1.01 | -1.28 | 18.21 | -2.20 |
| EV to Operating Cash Flow | 0.16 | 1.01 | -1.28 | 17.44 | -2.21 |
| Tangible Book Value Per Share | 0.25 | 1.09 | 1.37 | 2.75 | 3.58 |
| Shareholders’ Equity Per Share | 0.25 | 1.09 | 1.37 | 2.75 | 3.58 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.04 | 0.06 |
| Net Income Per Share | -1.09 | -1.27 | -1.83 | -1.37 | -1.20 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.94 | 0.97 | 1.00 |
| Research & Development to Revenue | 234.71 | 0.00 | 477.41 | 22.46 | 15.30 |
| SG&A to Revenue | 169.03 | 0.00 | 164.58 | 11.65 | 0.00 |
| Stock-Based Compensation to Revenue | 102.11 | 0.00 | 47.43 | 2.71 | 1.48 |
| Income Quality | 0.73 | 0.86 | 0.97 | -0.26 | 0.84 |
Currency in USD

